- Home
- RPRX vs EHC Comparison
RPRX vs EHC Comparison
Compare RPRX & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- EHC
- Stock Information
- Founded
- RPRX 1996
- EHC 1983
- Country
- RPRX United States
- EHC United States
- Employees
- RPRX N/A
- EHC N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- EHC Hospital/Nursing Management
- Sector
- RPRX Health Care
- EHC Health Care
- Exchange
- RPRX Nasdaq
- EHC Nasdaq
- Market Cap
- RPRX 13.9B
- EHC 12.3B
- IPO Year
- RPRX 2020
- EHC 1986
- Fundamental
- Price
- RPRX $35.59
- EHC $110.08
- Analyst Decision
- RPRX Strong Buy
- EHC Strong Buy
- Analyst Count
- RPRX 3
- EHC 8
- Target Price
- RPRX $48.33
- EHC $123.38
- AVG Volume (30 Days)
- RPRX 3.5M
- EHC 978.5K
- Earning Date
- RPRX 08-06-2025
- EHC 08-04-2025
- Dividend Yield
- RPRX 2.48%
- EHC 0.62%
- EPS Growth
- RPRX 37.60
- EHC 30.58
- EPS
- RPRX 2.45
- EHC 4.84
- Revenue
- RPRX $2,263,845,000.00
- EHC $5,512,600,000.00
- Revenue This Year
- RPRX $29.35
- EHC $10.75
- Revenue Next Year
- RPRX $7.58
- EHC $8.59
- P/E Ratio
- RPRX $14.47
- EHC $22.66
- Revenue Growth
- RPRX 1.13
- EHC 11.21
- 52 Week Low
- RPRX $24.05
- EHC $82.74
- 52 Week High
- RPRX $36.89
- EHC $123.13
- Technical
- Relative Strength Index (RSI)
- RPRX 52.61
- EHC 33.30
- Support Level
- RPRX $35.24
- EHC $105.70
- Resistance Level
- RPRX $36.89
- EHC $120.15
- Average True Range (ATR)
- RPRX 0.62
- EHC 3.05
- MACD
- RPRX -0.14
- EHC -1.25
- Stochastic Oscillator
- RPRX 22.16
- EHC 25.32
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.